圍手術期抗病毒治療可改善HBV相關肝細胞癌HBV DNA陰性患者的

StephenW

Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma
Chuan Li , Zhi-Cheng Li , Liang Ma , Le-Qun Li , Jian-Hong Zhong ORCID Icon, Bang-De Xiang & Wen-Feng Gong show less
Pages 749-756 | Received 27 Mar 2020, Accepted 16 Jun 2020, Accepted author version posted online: 18 Jun 2020, Published online: 30 Jun 2020

    Download citation https://doi.org/10.1080/17474124.2020.1784727 CrossMark Logo CrossMark

ABSTRACT
Objective

To investigate the effect of perioperative antiviral therapy on the prognosis of hepatitis B virus (HBV) DNA-negative patients with HBV-related hepatocellular carcinoma (HCC).
Methods

The clinical data of 140 patients who were positive for hepatitis B surface antigen (HBsAg) but negative for HBV DNA before partial hepatectomy were retrospectively analyzed. Propensity score matching (PSM) was used to eliminate the influence of confounding factors on prognosis. Postoperative liver function, HBV reactivation rate, recurrence-free survival (RFS) and overall survival (OS) were compared between antiviral and non-antiviral therapy groups.
Results

Compared with the non-antiviral therapy group, the antiviral therapy group had a lower rate of HBV reactivation and better postoperative liver function (P < 0.05). The 1-year, 2-year and 3-year survival rates of the antiviral therapy group were better than those of the non-antiviral therapy group before or after PSM (P < 0.05). Prognostic analysis excluding 11 patients with HBV reactivation showed that perioperative antiviral therapy could significantly improve OS (P = 0.004), but had no significant effect on RFS (P = 0.056). Multivariate analyzes showed that antiviral therapy was associated with better OS.
Conclusion

Perioperative antiviral therapy can significantly reduce the risk of HBV reactivation and improve postoperative liver function, RFS and OS.

StephenW

圍手術期抗病毒治療可改善HBV相關肝細胞癌HBV DNA陰性患者的預後
李傳立，李志成，馬良，李樂群，鍾建紅ORCID Icon，項邦德和龔文峰
第749-756頁於2020年3月27日收到，於2020年6月16日接受，在網上發表的作者版本：2020年6月18日，在線發表：2020年6月30日

    下載引文https://doi.org/10.1080/17474124.2020.1784727 CrossMark徽標CrossMark

抽象
目的

目的探討圍手術期抗病毒治療對乙型肝炎病毒（HBV）DNA陰性的HBV相關性肝細胞癌（HCC）患者預後的影響。
方法

回顧性分析140例部分肝切除術前乙型肝炎表面抗原（HBsAg）陽性但HBV DNA陰性的患者的臨床資料。傾向得分匹配（PSM）用於消除混雜因素對預後的影響。比較了抗病毒和非抗病毒治療組的術後肝功能，HBV激活率，無復發生存率（RFS）和總生存率（OS）。
結果

與非抗病毒治療組相比，抗病毒治療組的HBV再生率較低，術後肝功能更好（P <0.05）。 PSM前後，抗病毒治療組的1年，2年和3年生存率優於非抗病毒治療組（P <0.05）。排除11例HBV復活患者的預後分析表明，圍手術期抗病毒治療可以顯著改善OS（P = 0.004），但對RFS無顯著影響（P = 0.056）。多變量分析表明抗病毒治療與更好的OS有關。
結論

圍手術期抗病毒治療可以顯著降低HBV再次激活的風險，並改善術後肝功能，RFS和OS。